SCIENTIFIC AND SOCIAL PROGRAMME

SUNDAY, 28 AUGUST 2011

6.00 – 7.30 pm

REGISTRATION AND OPENING RECEPTION - CAMELOT ROOM,
THE CHATEAU ON THE PARK

MONDAY, 29 AUGUST 2011

8:00 - 9:00 am
REGISTRATION

9:00 am
Welcome and Announcements

1. ASCEPT PLENARY/SESSION 1

CHAIR: EVAN BEGG

9:05 am

PLENARY SPEAKER

Prof Carl MJ Kirkpatrick, Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia
Taking the piss in the critically ill: when 1+1 ≠ 2

10:00 am

1.2
Paul Chin, Christchurch Hospital, Christchurch
The performance of eGFR formulae for estimating gentamicin clearance

10:20 am

1.3
Lisa Stamp, University of Otago, Christchurch
Starting dose, but not maximum maintenance dose, is a risk factor for allopurinol hypersensitivity syndrome: a proposed nomogram for safe starting dose of allopurinol

10.40 am
Morning Tea
## 2. ASCEPT SESSION 2

**Chair: Jane Vella-Brincat**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15 am</td>
<td>2.1</td>
<td>Dan Wright, University of Otago, Dunedin</td>
<td>A population pharmacokinetic model for allopurinol in gout patients</td>
</tr>
<tr>
<td>11.30 am</td>
<td>2.2*</td>
<td>Julia Korell, University of Otago, Dunedin</td>
<td>Development and application of a pharmacokinetic model for the glycation of albumin</td>
</tr>
<tr>
<td>11:45 am</td>
<td>2.3</td>
<td>Hesham Al-Sallami, University of Otago, Dunedin</td>
<td>Estimating Fat Free Mass in Children</td>
</tr>
<tr>
<td>12.00 noon</td>
<td>2.4*</td>
<td>Claire Johnston, Royal North Shore Hospital, NSW, Australia</td>
<td>Population Pharmacokinetics of Gentamicin in Older People: The Impact of Frailty</td>
</tr>
<tr>
<td>12:15 pm</td>
<td>2.5</td>
<td>Evan Begg, University of Otago, Christchurch</td>
<td>Extended-interval gentamicin dosing in adult patients with impaired renal function – should the dose interval be extended further?</td>
</tr>
<tr>
<td>12.30 pm</td>
<td></td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>

## 3. ASCEPT SESSION 3

**Chair: Berit Jensen**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 pm</td>
<td>3.1</td>
<td>Nick Holford, University of Auckland, Auckland</td>
<td>Demonstration of symptomatic and disease modifying effects of levodopa in Parkinson’s disease using the ELLDOPA study</td>
</tr>
<tr>
<td>1.45 pm</td>
<td>3.2</td>
<td>Mark McKeage, University of Auckland, Auckland</td>
<td>Mass balance, metabolism and excretion of [14C]ASA404 in cancer patients</td>
</tr>
<tr>
<td>2.00 pm</td>
<td>3.3</td>
<td>Andrew McKean, Hillmorton Hospital, Christchurch</td>
<td>Is it NICE to monitor lithium routinely?</td>
</tr>
<tr>
<td>2.15 pm</td>
<td>3.4</td>
<td>Ganeesan Kichenadasse, Flinders Medical Centre, Adelaide, South Australia</td>
<td>In silico assessment of erlotinib as a potential inhibitor of CYP3A-mediated drug clearance</td>
</tr>
<tr>
<td>2.30 pm</td>
<td>3.5</td>
<td>Paul Zufferay, University of Otago, Dunedin</td>
<td>Fondaparinux: not so simple renal elimination</td>
</tr>
</tbody>
</table>

* For consideration for student prize
4. ASCEPT SESSION 4

**Chair: Paul Chin**

3.15 pm 4.1  
Steve Duffull, University of Otago, Dunedin
The current funding model leaves pharmacists caught in the struggle between justice and non-maleficence

3:30 pm 4.2*  
Ernieda Hatah, University of Otago, Dunedin
General practitioners’ perceptions of pharmacist prescribing in New Zealand

3.45 pm 4.3  
Jane Vella-Brincat, Christchurch Hospital, Christchurch
The pharmacokinetics of the antiemetic cyclizine, and how it feels to be subjected to blood sample orientated research, in palliative care

4:00 pm 4.4  
Melanie Gamble, Christchurch Hospital, Christchurch
An audit of adult acute epiglottitis antimicrobial guidelines

4.15 pm 4.5  
Pamela Buffery, Christchurch Hospital, Christchurch
A retrospective pharmacokinetic review of the busulphan monitoring service at Christchurch Hospital

4:30 pm  
ASCEPT AGM

7.00 pm  
**Conference Dinner in the Camelot Room,**  
**The Chateau on the Park**

* For consideration for student prize
8:30 – 9:00 am  CARNEY REGISTRATION

9:00 am  Welcome and Announcements

5. ASCEPT SESSION 5  
**Chair: Carl Kirpatrick**

9.05 am  5.1*  Christine Dixon, The University of Queensland, Queensland, Australia  
A high-throughput screen for novel drugs acting on the α2β2γ1 GABA<sub>A</sub> Receptor

9.20 am  5.2*  Matthew Bull, University of Auckland, Auckland  
Development of perforin inhibitors as pharmacological agents

9.35 am  5.3*  Nancy Jong, University of Auckland, Auckland  
Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in over-expressing HEK293 cells and rat dorsal root ganglion neurons

9.50 am  5.4*  FeiFei Feng, University of Otago, Dunedin  
Ketotifen uptake by rat brain endothelial (RBE4) cells is stereoselective

10.05 am  5.5*  Sarah Bushby, University of Otago, Dunedin  
Forensic investigations of a psychotropic drug using maggots in a brain model

10.20 am  5.6  Chakradhar Lagishetty, University of Otago, Dunedin  
Biomarkers of aging to predict drug clearance in the elderly - a pilot study

10:35 am  Morning Tea

* For consideration for student prize
6. **CARNEY PLENARY/SESSION 1**  

**Chair: Martin Kennedy**

11.05 am 6.1  
Prof Elizabeth J Phillips, Institute for Immunology and Infectious Diseases, Murdoch University, Perth, Australia  
Translating pharmacogenetics into the clinic

12.00 pm 6.2  
Richard Garry, University of Otago, Christchurch  
GWAS- an ignorant approach to genetics?

12.20 pm 6.3  
Berit Jensen, University of Otago, Christchurch  
LC-MS in clinical pharmacology and toxicology – from niche projects to routine screening

12.40 pm  
PRESENTATION OF FRED FASTIER TRUST STUDENT PRIZE

12.45 pm  
Lunch

7. **CARNEY SESSION 2**  

**Chair: Rebecca Roberts**

1:45 pm 7.1  
Hannah Kennedy, Christchurch Hospital, Christchurch  
Identification of multiple sclerosis patients who are non-responsive to therapeutic IFNβ: an assay to allow more informed treatment options.

2.00 pm 7.2  
Mei Zhang, University of Otago, Christchurch  
Determination of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in human red blood cells by LC-MS/MS

2.15 pm 7.3  
Nuala Helsby, University of Auckland, Auckland  
CYP2C19 poor metabolisers: who and why?

2.30 pm 7.4  
Murray Barclay, University of Otago, Christchurch  
High TMPT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment

2.45 pm  
Afternoon Tea
8. CARNEY SESSION 3

CHAIR: MURRAY BARCLAY

3.15 pm  8.1  Janet Coller, University of Adelaide, Adelaide, Australia
 Association between immune genetic markers and alcohol dependence

3.35 pm  8.2  Rebecca Roberts, University of Otago, Dunedin
 The benz bromarone story - is CYP2C9 genotype relevant to prescribing?

3.55 pm  8.3  Patrick Gladding, University of Auckland, Auckland
 Personalised thienopyridine therapy: the cost effectiveness of genetic testing for CYP2C19 variants to guide treatment in patients with acute coronary syndromes

4.15 pm  CLOSING STATEMENT AND SESSION CLOSED